Skip to main content
Erschienen in: Herz 5/2014

01.08.2014 | e-Herz: Original article

Transthoracic echocardiographic and cardiopulmonary exercise testing parameters in Eisenmenger’s syndrome

Association with six-minute walk test distance

verfasst von: H. Gungor, MD, M. Fatih Ayik, C. Engin, T. Yagdi, Y. Atay, M. Ozbaran, S. Nalbantgil

Erschienen in: Herz | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

The six-minute walk test (6MWT) evaluates the functional exercise capacity in patients with cardiopulmonary disease. We aimed to investigate the association between 6MWT distance and transthoracic echocardiographic (TTE) findings as well as cardiopulmonary exercise testing (CPET) parameters in Eisenmenger’s syndrome (ES) patients waiting for heart–lung transplantation on their initial admission to our center.

Patients and methods

A total of 23 patients with ES (12 women, 11 men; mean age, 28.2 ± 8.1 years) were included in the study. The correlation between 6MWT distance and CPET and TTE findings was retrospectively analyzed.

Results

The most frequent underlying heart diseases were ventricular septal defect (VSD) with complex congenital heart disease (n = 10, 43 %) and isolated VSD (n = 7, 30 %). The 6MWT distance was 349.7 ± 77.4 m in the study group. An inverse correlation was found between 6MWT distance and systolic pulmonary arterial pressure (SPAP) measured with TTE (r = − 0.445; p = 0.03). All patients underwent CPET at the first visit. Mean VO2 max was 14.9 ± 3.3 ml/kg/min and the VE/VCO2 rate was 50.4 ± 9.2 %. No significant correlation was observed between 6MWT and CPET findings. SPAP, which did not display any correlation with CPET findings, was the only independent predictor of 6MWT distance.

Conclusion

We suggest that 6MWT distance may be more suitable than CPET in the follow-up of ES patients. Further prospective, randomized, controlled trials are necessary to make more robust interpretations of this issue.
Literatur
1.
Zurück zum Zitat Eisenmenger V (1897) Die angeborenen Defecte der Kammerssheidewand des Herzens. Z Klin Med 32:1–28 Eisenmenger V (1897) Die angeborenen Defecte der Kammerssheidewand des Herzens. Z Klin Med 32:1–28
3.
Zurück zum Zitat n d (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117 n d (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117
4.
Zurück zum Zitat Camarri B, Eastwood PR, Cecins NM et al (2006) Six minute walk distance in healthy subjects aged 55–75 years. Respir Med 100:658–665PubMedCrossRef Camarri B, Eastwood PR, Cecins NM et al (2006) Six minute walk distance in healthy subjects aged 55–75 years. Respir Med 100:658–665PubMedCrossRef
5.
Zurück zum Zitat Gibbons WJ, Fruchter N, Sloan S et al (2001) Reference values for a multiple repetition 6 min. walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 21:87–93PubMedCrossRef Gibbons WJ, Fruchter N, Sloan S et al (2001) Reference values for a multiple repetition 6 min. walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 21:87–93PubMedCrossRef
6.
Zurück zum Zitat Demir R, Kucukoglu MS (2010) Evaluation of exercise capacity in pulmonary arterial hypertension. Turk Kardiyol Dern Ars 38:580–588PubMed Demir R, Kucukoglu MS (2010) Evaluation of exercise capacity in pulmonary arterial hypertension. Turk Kardiyol Dern Ars 38:580–588PubMed
7.
Zurück zum Zitat Enright PL, Sherrill DL (1998) Reference equations for the six minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387PubMed Enright PL, Sherrill DL (1998) Reference equations for the six minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387PubMed
8.
Zurück zum Zitat n d (2003) ATS/ACCP statement on cardiopulmonary exercise testing Am J Respir Care Med 167:211–217 n d (2003) ATS/ACCP statement on cardiopulmonary exercise testing Am J Respir Care Med 167:211–217
9.
Zurück zum Zitat Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296–301PubMedCrossRef Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296–301PubMedCrossRef
10.
Zurück zum Zitat Hinderliter AL, Willis PW, Barst RJ et al (1997) Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 95:1479–1486PubMedCrossRef Hinderliter AL, Willis PW, Barst RJ et al (1997) Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 95:1479–1486PubMedCrossRef
11.
Zurück zum Zitat Lipkin D, Scriven AJ, Crake T et al (1986) Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J 292:653–655CrossRef Lipkin D, Scriven AJ, Crake T et al (1986) Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J 292:653–655CrossRef
12.
Zurück zum Zitat Cahalin L, Mathier MA, Semigran MJ et al (1996) The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 110:325–332PubMedCrossRef Cahalin L, Mathier MA, Semigran MJ et al (1996) The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 110:325–332PubMedCrossRef
13.
Zurück zum Zitat Faggiano P, D’Aloia A, Gualeni A et al (1997) Assessment of oxygen uptake during the 6-minute walking test in patients with heart failure: preliminary experience with a portable device. Am Heart J 134:203–206PubMedCrossRef Faggiano P, D’Aloia A, Gualeni A et al (1997) Assessment of oxygen uptake during the 6-minute walking test in patients with heart failure: preliminary experience with a portable device. Am Heart J 134:203–206PubMedCrossRef
15.
Zurück zum Zitat Reesink HJ, Plas MN van der, Verhey NE et al (2007) Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 133:510–516PubMedCrossRef Reesink HJ, Plas MN van der, Verhey NE et al (2007) Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 133:510–516PubMedCrossRef
16.
Zurück zum Zitat Hodgev VA, Aliman OI, Marinov BI et al (2003) Cardiovascular and dyspnea response to six-minute and shuttle walk tests in COPD patients. Folia Med 45:26–33 Hodgev VA, Aliman OI, Marinov BI et al (2003) Cardiovascular and dyspnea response to six-minute and shuttle walk tests in COPD patients. Folia Med 45:26–33
17.
Zurück zum Zitat Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487–492PubMed Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487–492PubMed
18.
Zurück zum Zitat Rovedder PM, Ziegler B, Pasin LR et al (2008) Doppler echocardiogram, oxygen saturation and submaximum capacity of exercise in patients with cystic fibrosis. J Bras Pneumol 34:83–90PubMedCrossRef Rovedder PM, Ziegler B, Pasin LR et al (2008) Doppler echocardiogram, oxygen saturation and submaximum capacity of exercise in patients with cystic fibrosis. J Bras Pneumol 34:83–90PubMedCrossRef
Metadaten
Titel
Transthoracic echocardiographic and cardiopulmonary exercise testing parameters in Eisenmenger’s syndrome
Association with six-minute walk test distance
verfasst von
H. Gungor, MD
M. Fatih Ayik
C. Engin
T. Yagdi
Y. Atay
M. Ozbaran
S. Nalbantgil
Publikationsdatum
01.08.2014
Verlag
Urban & Vogel
Erschienen in
Herz / Ausgabe 5/2014
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-013-3880-5

Weitere Artikel der Ausgabe 5/2014

Herz 5/2014 Zur Ausgabe

CME Zertifizierte Fortbildung

Kardiale Probleme in der Schwangerschaft

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.